Drug Trial Radar · NCT07760467
To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Aug 26, 2026
Primary completion
May 8, 2027
Study completion May 8, 2027
Sponsor
- Lead sponsor
- Zhuhai United Laboratories Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I Study Evaluating Safety, Tolerability, PK and PD of Single and Multiple Doses of TUL321 Capsule in Healthy Participants and Food Effect on PK
Conditions
- Paroxysmal Nocturnal Hemoglobinuria, PNH
Interventions
Part1: TUL321Drug
orally, 20 mg、50 mg、 100 mg、200 mg、400 mg and 600 mg
Part1: PlaceboDrug
Oral placebo capsules matching TUL321 capsules
Part2: TUL321Drug
orally, 50 mg QD、100 mg QD、300 mg QD、50 mg BID
Part2: PlaceboDrug
Oral placebo capsules matching TUL321 capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1.Incidence of adverse events (AEs) 2.Changes from baseline in physical examinations, vital signs, electrocardiograms (ECG), and laboratory testsTime frame: up to 17 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.